US206877A
(en)
*
|
|
1878-08-13 |
|
Improvement in paper-pulp washers |
JPS5328173A
(en)
|
1976-08-06 |
1978-03-16 |
Zenyaku Kogyo Kk |
Novel phenylmethanenitro compound and its preparation
|
US4138397A
(en)
|
1978-02-27 |
1979-02-06 |
Richardson-Merrell Inc. |
6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
JPS61103861A
(ja)
|
1984-10-27 |
1986-05-22 |
Nitto Kasei Kk |
アリ−ル置換シアン酢酸エステルの製造方法
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
US5886026A
(en)
|
1993-07-19 |
1999-03-23 |
Angiotech Pharmaceuticals Inc. |
Anti-angiogenic compositions and methods of use
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH10213820A
(ja)
|
1997-01-31 |
1998-08-11 |
Canon Inc |
液晶素子及び液晶装置
|
WO1998047868A1
(en)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
|
DE69831233T2
(de)
|
1997-06-21 |
2006-06-01 |
Roche Diagnostics Gmbh |
Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
|
DK0901786T3
(da)
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
CN1283995A
(zh)
|
1997-12-11 |
2001-02-14 |
生化制药有限公司 |
抗病毒化合物
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
PT1394150E
(pt)
|
1999-02-24 |
2011-02-17 |
Hoffmann La Roche |
Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
|
DE60028791T2
(de)
|
1999-09-10 |
2007-05-24 |
Novo Nordisk A/S |
Modulatoren der protein tyrosin phosphatase (ptpases)
|
WO2001019831A1
(en)
|
1999-09-10 |
2001-03-22 |
Novo Nordisk A/S |
MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
|
AUPQ288499A0
(en)
|
1999-09-16 |
1999-10-07 |
Biota Scientific Management Pty Ltd |
Antiviral agents
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
IT1315267B1
(it)
|
1999-12-23 |
2003-02-03 |
Novuspharma Spa |
Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
|
AU2001229501A1
(en)
|
2000-01-24 |
2001-07-31 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of inducible nitric oxide synthase expression
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
DE10038019A1
(de)
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Substituierte Triazolopyrid(az)ine
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6562989B2
(en)
|
2000-08-07 |
2003-05-13 |
Yale University |
Catalyst for aromatic C—O, C—N, and C—C bond formation
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
AR030357A1
(es)
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
DE60137273D1
(de)
|
2000-10-20 |
2009-02-12 |
Eisai R&D Man Co Ltd |
Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
GB0102109D0
(en)
|
2001-01-26 |
2001-03-14 |
Syngenta Ltd |
Chemical process
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
EP1383799A4
(en)
|
2001-04-10 |
2008-08-06 |
Transtech Pharma Inc |
PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
|
ATE449763T1
(de)
|
2001-04-16 |
2009-12-15 |
Eisai R&D Man Co Ltd |
1h-indazolverbindungen die jnk hemmen
|
MXPA03011707A
(es)
|
2001-06-28 |
2004-03-19 |
Pfizer Prod Inc |
Compuestos heterobiciclicos sustituidos con triamida.
|
CA2448737C
(en)
|
2001-07-20 |
2010-06-01 |
Boehringer Ingelheim (Canada) Ltd. |
Viral polymerase inhibitors
|
AUPR738301A0
(en)
|
2001-08-30 |
2001-09-20 |
Starpharma Limited |
Chemotherapeutic agents
|
JP4343690B2
(ja)
|
2001-11-13 |
2009-10-14 |
メルク フロスト カナダ リミテツド |
プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体
|
EP1458693A4
(en)
|
2001-11-14 |
2005-02-09 |
Teva Pharma |
Amorphous and crystalline forms of losartan potassium and method for making same
|
AU2002351748B2
(en)
|
2001-12-21 |
2009-07-09 |
Novo Nordisk A/S |
Amide derivatives as GK activators
|
US20030158188A1
(en)
|
2002-02-20 |
2003-08-21 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US7074805B2
(en)
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US20040009956A1
(en)
|
2002-04-29 |
2004-01-15 |
Dehua Pei |
Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
|
WO2004002481A1
(en)
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
EP1541563A4
(en)
|
2002-07-10 |
2007-11-07 |
Ono Pharmaceutical Co |
ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US20060083784A1
(en)
|
2002-08-07 |
2006-04-20 |
Smithkline Beecham Corporation |
Amorphous pharmaceutical compositions
|
EP1541574A4
(en)
|
2002-09-18 |
2007-06-20 |
Ono Pharmaceutical Co |
TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT
|
WO2004028480A2
(en)
|
2002-09-30 |
2004-04-08 |
The Regents Of The University Of California |
Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
|
JP2004131393A
(ja)
|
2002-10-08 |
2004-04-30 |
Kowa Co |
易溶出性製剤
|
EP1554271A1
(en)
|
2002-10-15 |
2005-07-20 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
FR2846327B1
(fr)
|
2002-10-25 |
2006-03-24 |
Merck Sante Sas |
Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
|
AU2003286757B2
(en)
|
2002-11-01 |
2009-06-04 |
Merck Sharp & Dohme Corp. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
DE10251019A1
(de)
|
2002-11-02 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
|
BR0315055A
(pt)
|
2002-11-02 |
2005-08-16 |
Aventis Pharma Gmbh |
Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
DE10300017A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Selektive MMP 13 Inhibitoren
|
KR101076018B1
(ko)
|
2003-01-08 |
2011-10-21 |
유니버시티 오브 워싱톤 |
항균제
|
US6933311B2
(en)
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
DE602004024375D1
(de)
|
2003-02-14 |
2010-01-14 |
Glaxo Group Ltd |
Carboxamidderivate
|
DE10306941A1
(de)
|
2003-02-18 |
2004-08-26 |
Merck Patent Gmbh |
Benzofuranoxyethylamine
|
WO2004080972A1
(en)
|
2003-03-12 |
2004-09-23 |
Vertex Pharmaceuticals Incorporated |
Pirazole modulators of atp-binding cassette transporters
|
US20050164951A1
(en)
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
DE10315377A1
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Carbonylverbindungen
|
EP1720844B1
(de)
|
2003-04-03 |
2009-04-29 |
MERCK PATENT GmbH |
Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
|
SI3632902T1
(sl)
|
2003-04-11 |
2022-01-31 |
Ptc Therapeutics, Inc. |
Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
|
EP1787982B1
(en)
|
2003-04-11 |
2010-05-12 |
High Point Pharmaceuticals, LLC |
11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
|
US7696244B2
(en)
|
2003-05-16 |
2010-04-13 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
|
WO2004111014A1
(en)
|
2003-06-06 |
2004-12-23 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
WO2005002519A2
(en)
|
2003-06-27 |
2005-01-13 |
Henry M.Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Amphiphilic pyridinium compounds, method of making and use thereof
|
US20050113576A1
(en)
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US7834008B2
(en)
|
2003-08-15 |
2010-11-16 |
H. Lundbeck A/S |
Cyclopropyl derivatives as NK3 receptor antagonists
|
JP2007504255A
(ja)
|
2003-09-06 |
2007-03-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atp結合カセットトランスポーターの調節因子
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
EP1680411A2
(en)
|
2003-10-08 |
2006-07-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
|
WO2005037802A1
(ja)
|
2003-10-16 |
2005-04-28 |
Sankyo Company, Limited |
5-アリールピリミジン誘導体
|
WO2005040135A1
(ja)
|
2003-10-24 |
2005-05-06 |
Ono Pharmaceutical Co., Ltd. |
抗ストレス薬およびその医薬用途
|
DE602004022319D1
(de)
|
2003-11-14 |
2009-09-10 |
Vertex Pharma |
Thiazole udn oxazole als modulatoren von atp-bindungs-kassetten-transportern
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP3219709B1
(en)
|
2004-01-30 |
2020-03-18 |
Vertex Pharmaceuticals Incorporated |
Intermediate compound of modulators of atp-binding cassette transporters
|
MXPA06008507A
(es)
|
2004-02-02 |
2008-02-13 |
Ambrx Inc |
Cuatro polipeptidos en haz helicoidal humanos modificados y sus usos.
|
EP1740532A4
(en)
|
2004-03-30 |
2009-06-10 |
Univ California |
CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
|
US20050222271A1
(en)
|
2004-03-31 |
2005-10-06 |
Le Huang |
Novel amorphous form of memantine hydrochloride
|
FR2868417B1
(fr)
|
2004-04-02 |
2006-06-23 |
Rhodia Chimie Sa |
Procede de formation d'une liaison carbone-carbone
|
US20080138803A1
(en)
|
2004-06-01 |
2008-06-12 |
Galvan-Goldman Nee Galvan Barb |
Method of Detecting Cystic Fibrosis Associated Mutations
|
CA2569402A1
(en)
|
2004-06-04 |
2005-12-22 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
US7495103B2
(en)
|
2004-06-24 |
2009-02-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
GB0416730D0
(en)
|
2004-07-27 |
2004-09-01 |
Novartis Ag |
Organic compounds
|
AU2005268030B2
(en)
|
2004-08-06 |
2009-02-19 |
Otsuka Pharmaceutical Co., Ltd. |
Aromatic compounds
|
DE102004047254A1
(de)
|
2004-09-29 |
2006-04-13 |
Merck Patent Gmbh |
Carbonylverbindungen
|
EP1799207A2
(en)
|
2004-10-13 |
2007-06-27 |
PTC Therapeutics, Inc. |
Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
|
WO2006045119A2
(en)
|
2004-10-20 |
2006-04-27 |
The Regents Of The University Of California |
Improved inhibitors for the soluble epoxide hydrolase
|
WO2006057448A1
(ja)
|
2004-11-26 |
2006-06-01 |
Takeda Pharmaceutical Company Limited |
アリールアルカン酸誘導体
|
EP1676834A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Sanofi-Aventis Deutschland GmbH |
Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
|
KR101377790B1
(ko)
|
2005-02-25 |
2014-03-27 |
오노 야꾸힝 고교 가부시키가이샤 |
인돌 화합물 및 이의 용도
|
WO2006099256A2
(en)
|
2005-03-11 |
2006-09-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
RU2007138584A
(ru)
|
2005-03-18 |
2009-04-27 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) |
Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение
|
US20100120789A1
(en)
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
SG155251A1
(en)
|
2005-03-28 |
2009-09-30 |
Toyama Chemical Co Ltd |
Process for production of 1-(3-(2-(1-benzothiophen-5-yl)- ethoxy)propyl)azetidin-3-ol or salts thereof
|
JP2006282534A
(ja)
|
2005-03-31 |
2006-10-19 |
Fuji Photo Film Co Ltd |
アミド類の製造方法
|
PL1874306T3
(pl)
|
2005-04-08 |
2012-11-30 |
Ptc Therapeutics Inc |
Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji
|
EP1877401A2
(en)
|
2005-04-15 |
2008-01-16 |
Elan Pharmaceuticals Inc. |
Novel compounds useful for bradykinin b1 receptor antagonism
|
CN101223146A
(zh)
|
2005-05-24 |
2008-07-16 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
WO2007021982A2
(en)
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CN101287732A
(zh)
|
2005-08-11 |
2008-10-15 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜电导调节剂的调控剂
|
DK1926476T3
(da)
|
2005-08-29 |
2013-07-01 |
Sanofi Aventis Us Llc |
Amorfe faste dispersioner af 7-chlor-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid
|
US8314256B2
(en)
|
2005-10-06 |
2012-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US20070219192A1
(en)
|
2005-11-02 |
2007-09-20 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
CN102775396B
(zh)
|
2005-11-08 |
2014-10-08 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的杂环调控剂
|
GB0525144D0
(en)
|
2005-12-09 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
MX2008008277A
(es)
|
2005-12-21 |
2009-03-04 |
Janssen Pharmaceutica Nv |
Triazolopiridazinas como moduladores de tirosina cinasa.
|
WO2007075901A2
(en)
|
2005-12-24 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Quinolin- 4 - one derivatives as modulators of abc transporters
|
EP1974212A1
(en)
|
2005-12-27 |
2008-10-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
CA2856037C
(en)
|
2005-12-28 |
2017-03-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
RS55940B1
(sr)
|
2005-12-28 |
2017-09-29 |
Vertex Pharma |
Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
|
TW200808723A
(en)
|
2006-03-13 |
2008-02-16 |
Univ California |
Conformationally restricted urea inhibitors of soluble epoxide hydrolase
|
AU2007226983A1
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
TWI428125B
(zh)
|
2006-03-20 |
2014-03-01 |
Vertex Pharma |
對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
|
JP2009530399A
(ja)
|
2006-03-22 |
2009-08-27 |
シンデクサ ファーマシューティカルズ コーポレーション |
Erストレスに関連する疾病の治療のための化合物及び方法
|
EP2007365A2
(en)
*
|
2006-03-30 |
2008-12-31 |
PTC Therapeutics, Inc. |
Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
PL2007756T3
(pl)
|
2006-04-07 |
2016-01-29 |
Vertex Pharma |
Modulatory transporterów posiadających kasetę wiążącą ATP
|
AU2007249269A1
(en)
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CA2691214A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2008020227A2
(en)
|
2006-08-17 |
2008-02-21 |
Astrazeneca Ab |
Antibacterial pyrrolecarboxamides
|
WO2008029152A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
WO2008029168A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
PT2081937E
(pt)
|
2006-10-23 |
2012-10-15 |
Sgx Pharmaceuticals Inc |
Moduladores de proteína-cinase de triazolo-piridazina
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
RU2009120976A
(ru)
|
2006-11-03 |
2010-12-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Производные азаиндола в качестве модуляторов cftr
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
US20080132560A1
(en)
|
2006-11-21 |
2008-06-05 |
San-Laung Chow |
Solid dispersion composition
|
JPWO2008065732A1
(ja)
|
2006-11-27 |
2010-03-04 |
日本ポリウレタン工業株式会社 |
アロファネート結合及びイソシアヌレート結合含有変性イソシアネート混合物の製造方法
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
US8969386B2
(en)
|
2007-05-09 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
JP5686596B2
(ja)
|
2007-05-25 |
2015-03-18 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
|
US8557823B2
(en)
|
2007-06-18 |
2013-10-15 |
Advanced Cancer Therapeutics, Llc |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
WO2008156783A2
(en)
|
2007-06-18 |
2008-12-24 |
University Of Louisville Research Foundation, Inc. |
Family of pfkfb3 inhibitors with anti-neoplastic activities
|
MX2009014159A
(es)
|
2007-07-19 |
2010-03-04 |
Lundbeck & Co As H |
Amidas heterocíclicas de 5-miembros y compuestos relacionados.
|
US20110177999A1
(en)
|
2007-08-09 |
2011-07-21 |
Vertex Pharmaceuticals Incorporated |
Therapeutic Combinations Useful in Treating CFTR Related Diseases
|
JP5389030B2
(ja)
|
2007-08-24 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
(特に)嚢胞性線維症の処置に有用なイソチアゾロピリジノン
|
AU2008301907B2
(en)
|
2007-09-14 |
2014-02-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
JP5461405B2
(ja)
|
2007-09-14 |
2014-04-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症膜コンダクタンス制御因子の調節因子
|
US8673911B2
(en)
|
2007-11-02 |
2014-03-18 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
SI2578571T1
(sl)
|
2007-11-16 |
2016-01-29 |
Vertex Pharmaceuticals Incorporated |
Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
|
DK2409975T3
(en)
|
2007-11-22 |
2015-08-03 |
Zenyaku Kogyo Kk |
Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
|
WO2009076141A2
(en)
|
2007-12-07 |
2009-06-18 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
PL2231606T3
(pl)
|
2007-12-07 |
2013-07-31 |
Vertex Pharma |
Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
|
KR20160040745A
(ko)
|
2007-12-07 |
2016-04-14 |
버텍스 파마슈티칼스 인코포레이티드 |
3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
|
CA2709301C
(en)
|
2007-12-13 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20090247521A1
(en)
|
2007-12-28 |
2009-10-01 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
ES2647531T3
(es)
|
2008-02-28 |
2017-12-22 |
Vertex Pharmaceuticals Incorporated |
Derivados de heteroarilo como moduladores de CFTR
|
PT2615085E
(pt)
|
2008-03-31 |
2015-10-09 |
Vertex Pharma |
Derivados piridilo como moduladores cftr
|
WO2009127822A2
(en)
|
2008-04-16 |
2009-10-22 |
Biolipox Ab |
Bis-aryl compounds for use as medicaments
|
US20090270452A1
(en)
|
2008-04-18 |
2009-10-29 |
Arete Therapeutics, Inc. |
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
MX2010011209A
(es)
|
2008-04-24 |
2010-11-12 |
Squibb Bristol Myers Co |
Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
US9447049B2
(en)
|
2010-03-01 |
2016-09-20 |
University Of Tennessee Research Foundation |
Compounds for treatment of cancer
|
PL2328618T3
(pl)
|
2008-08-13 |
2018-06-29 |
Vertex Pharmaceuticals Incorporated |
Kompozycja farmaceutyczna n-[2,4-bis(1,1-dimetyloetylo)5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu i jej podawanie
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
US8895781B2
(en)
|
2008-09-04 |
2014-11-25 |
Georgetown University |
Transition metal-catalyzed C—H amination using unactivated amines
|
AR073578A1
(es)
|
2008-09-15 |
2010-11-17 |
Priaxon Ag |
Pirrolidin-2-onas
|
BRPI0919550A2
(pt)
|
2008-09-29 |
2019-09-10 |
Vertex Pharma |
unidades de dosagem de ácido 3-(6-(1-(2,2-difluorobenzo]d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
AR074060A1
(es)
|
2008-10-23 |
2010-12-22 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
|
AU2009308232B2
(en)
|
2008-10-23 |
2016-02-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
ES2406361T3
(es)
|
2008-10-23 |
2013-06-06 |
Vertex Pharmaceuticals Incorporated |
Formas sólidas de la N-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-carboxamida
|
UA104876C2
(ru)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модуляторы атф-связывающих кассетных транспортеров
|
CN108117546A
(zh)
|
2008-11-06 |
2018-06-05 |
弗特克斯药品有限公司 |
Atp-结合盒转运蛋白调节剂
|
EP2384328B1
(en)
|
2008-11-27 |
2013-02-13 |
Boehringer Ingelheim International GmbH |
6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US9120779B2
(en)
|
2008-12-03 |
2015-09-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
EP2382197B1
(en)
|
2008-12-30 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US8946419B2
(en)
|
2009-02-23 |
2015-02-03 |
Mallinckrodt Llc |
(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
|
KR20100101054A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
PT2408749T
(pt)
|
2009-03-20 |
2018-10-08 |
Vertex Pharma |
Moduladores do regulador da condutância transmembranar da fibrose cística
|
SG174410A1
(en)
|
2009-03-20 |
2011-11-28 |
Vertex Pharma |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
DK2419429T3
(da)
|
2009-04-16 |
2014-06-23 |
Ct Nac De Investigaciones Oncológicas Cnio |
Imidazopyraziner som inhibitorer af proteinkinaser
|
WO2011005355A1
(en)
|
2009-05-07 |
2011-01-13 |
Achaogen, Inc. |
Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
|
CA2761639C
(en)
|
2009-05-29 |
2016-06-07 |
Raqualia Pharma Inc. |
Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
|
EP2264012A1
(de)
|
2009-06-03 |
2010-12-22 |
Bayer CropScience AG |
Heteroarylamidine und deren Verwendung als Fungizide
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
WO2011029832A1
(de)
|
2009-09-09 |
2011-03-17 |
Vifor (International) Ag |
Neue thiazol- und oxazol-hepcidin-antagonisten
|
CA2772792A1
(en)
|
2009-09-17 |
2011-03-24 |
Vertex Pharmaceuticals Incorporated |
Process for preparing azabicyclic compounds
|
SG179112A1
(en)
|
2009-09-18 |
2012-04-27 |
Univ Nanyang Tech |
Process of forming an amide
|
EP2490687A1
(en)
|
2009-10-22 |
2012-08-29 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
KR20120102645A
(ko)
|
2009-10-23 |
2012-09-18 |
버텍스 파마슈티칼스 인코포레이티드 |
N-(4-(7-아자비시클로[2.2.1]헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복사미드의 고체 형태
|
KR20120104554A
(ko)
|
2009-10-23 |
2012-09-21 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
AU2010347233B2
(en)
|
2010-03-01 |
2015-06-18 |
Oncternal Therapeutics, Inc. |
Compounds for treatment of cancer
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
NZ602557A
(en)
|
2010-03-19 |
2014-09-26 |
Vertex Pharma |
Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
ES2845449T3
(es)
*
|
2010-03-25 |
2021-07-26 |
Vertex Pharma |
Dispersión sólida de forma amorfa de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2(1-hidroxi-2-metilpropan-2-il)-1h-indol-5il)-ciclopropanocarboxamida
|
SI2555754T1
(sl)
|
2010-04-07 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Trdne farmacevtske oblike 3-(6-(1-(2,2-difluoro-benzo(d)(1,3)dioksol-5- il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
|
PT3150198T
(pt)
|
2010-04-07 |
2021-12-22 |
Vertex Pharma |
Composições farmacêuticas de ácido 3-(6-(1-(2,2 difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e sua administração
|
SG184987A1
(en)
|
2010-04-22 |
2012-11-29 |
Vertex Pharma |
Process of producing cycloalkylcarboxamido-indole compounds
|
EP2560651A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
WO2011133951A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
NZ603043A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP2386606B1
(fr)
|
2010-04-30 |
2018-03-21 |
Total Marketing Services |
Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
|
WO2011146886A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
KR101945324B1
(ko)
|
2010-05-20 |
2019-02-07 |
셈프라 파마슈티컬스, 인크. |
매크로라이드들 및 케톨라이드들과 이의 중간체들을 제조하는 공정들
|
AU2011255237A1
(en)
|
2010-05-20 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120149708A1
(en)
|
2010-06-17 |
2012-06-14 |
George Mason University |
Modulators of viral transcription, and methods and compositions therewith
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
AU2011293658B2
(en)
|
2010-08-23 |
2015-03-05 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
BR112013004130A2
(pt)
|
2010-08-27 |
2016-07-05 |
Vertex Pharma |
composição farmacêutica e administrações da mesma
|
WO2012049555A1
(en)
|
2010-10-13 |
2012-04-19 |
Lupin Limited |
Spirocyclic compounds as voltage-gated sodium channel modulators
|
US9394290B2
(en)
|
2010-10-21 |
2016-07-19 |
Universitaet Des Saarlandes Campus Saarbruecken |
Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2012079583A1
(en)
|
2010-12-15 |
2012-06-21 |
Aarhus Universitet |
System providing controlled delivery of gaseous co for carbonylation reactions
|
WO2012116135A2
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Noggin blocking compositions for ossification and methods related thereto
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
CN102731492B
(zh)
|
2011-03-30 |
2016-06-29 |
江苏恒瑞医药股份有限公司 |
环己烷类衍生物、其制备方法及其在医药上的应用
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
CN104159890B
(zh)
|
2011-09-09 |
2018-04-10 |
蓝瑟斯医学影像公司 |
用于合成和使用显像剂的组合物、方法和系统
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
CA2853299A1
(en)
|
2011-11-02 |
2013-05-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases
|
WO2013070961A1
(en)
|
2011-11-08 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
WO2013086131A1
(en)
|
2011-12-06 |
2013-06-13 |
The Trustees Of The University Of Pennsylvania |
Inhibitors targeting drug-resistant influenza a
|
US8772541B2
(en)
|
2011-12-15 |
2014-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
|
EP2606726A1
(de)
|
2011-12-21 |
2013-06-26 |
Bayer CropScience AG |
N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
|
PT2806859T
(pt)
|
2012-01-25 |
2019-09-04 |
Vertex Pharma |
Formulações de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
薬学的組成物およびその投与
|
US9217050B2
(en)
|
2012-04-03 |
2015-12-22 |
3M Innovative Properties Company |
Crosslinkable composition comprising photobase generators
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US9228101B2
(en)
|
2012-04-26 |
2016-01-05 |
Xerox Corporation |
Rapidly crystallizing phase change inks and methods for forming the same
|
US20130284054A1
(en)
|
2012-04-26 |
2013-10-31 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
US9528016B2
(en)
|
2012-04-26 |
2016-12-27 |
Xerox Corporation |
Phase change inks comprising crystalline amides
|
US8888905B2
(en)
|
2012-04-26 |
2014-11-18 |
Xerox Corporation |
Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
|
CA2813472A1
(en)
|
2012-04-26 |
2013-10-26 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
EP2861577B1
(en)
|
2012-05-25 |
2017-01-04 |
Boehringer Ingelheim International GmbH |
Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
|
GB2502624A
(en)
|
2012-06-01 |
2013-12-04 |
Univ East Anglia |
Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
|
US8889857B2
(en)
|
2012-06-08 |
2014-11-18 |
Massachusetts Institute Of Technology |
Phosphine-ligated palladium sulfonate palladacycles
|
AU2013270681A1
(en)
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
FR2992317B1
(fr)
|
2012-06-22 |
2016-05-13 |
Diverchim |
Procede de preparation de peptides chiraux
|
WO2014002106A1
(en)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Novel compounds for the treatment of dyslipidemia and related diseases
|
RU2663110C2
(ru)
|
2012-07-12 |
2018-08-01 |
ПРОКЬЮЭР ТЕРАПЬЮТИКС II Би.Ви. |
Олигонуклеотиды для введения изменения в последовательность молекулы целевой рнк в живой клетке
|
WO2014011050A1
(en)
|
2012-07-12 |
2014-01-16 |
Proqr Therapeutics B.V. |
Exon replacement with stabilized artificial rnas
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
CN104812382A
(zh)
|
2012-09-20 |
2015-07-29 |
坦普尔大学 |
取代的烷基二芳基衍生物、制备方法和用途
|
BR102012025405A2
(pt)
|
2012-10-05 |
2014-10-07 |
Univ Brasilia Fudacao |
Processo de obtenção de amidas via aminólise catalítica de ésteres e ácidos carboxílicos em líquidos iônicos
|
JPWO2014068893A1
(ja)
|
2012-10-29 |
2016-09-08 |
コニカミノルタ株式会社 |
位相差フィルム、円偏光板、及び画像表示装置
|
WO2014071122A1
(en)
|
2012-11-02 |
2014-05-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cftr mediated diseases
|
US9757379B2
(en)
|
2012-11-14 |
2017-09-12 |
The Board Of Regents Of The University Of Texas System |
Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
EA030814B1
(ru)
|
2012-11-20 |
2018-10-31 |
Мериал, Инк. |
Антигельминтные соединения, композиции и способы их применения
|
ITMI20122065A1
(it)
|
2012-12-03 |
2014-06-04 |
Univ Padova |
Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
|
EP2929346A1
(en)
|
2012-12-05 |
2015-10-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Diagnosis of cystic fibrosis
|
EP2928532A4
(en)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
NOSE CANNULA FOR THE ADMINISTRATION OF MEDICAMENTS IN AEROSOL FORM
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
CN105531268B
(zh)
|
2013-05-07 |
2017-09-12 |
加拉佩格斯股份有限公司 |
用于治疗囊性纤维化的新化合物及其药物组合物
|
EP3004083A4
(en)
|
2013-05-24 |
2016-11-16 |
California Inst Biomedical Res |
COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
|
JP2014232188A
(ja)
|
2013-05-29 |
2014-12-11 |
コニカミノルタ株式会社 |
セルロースアシレートフィルム、円偏光板及び画像表示装置
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
LT3030568T
(lt)
|
2013-08-08 |
2018-12-27 |
Galapagos Nv |
Tieno[2,3-c]piranai, kaip cftr moduliatoriai
|
US9688990B2
(en)
|
2013-09-12 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
US10882834B2
(en)
|
2013-09-20 |
2021-01-05 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Compounds for treating prostate cancer
|
EP3052190A4
(en)
|
2013-10-01 |
2017-07-19 |
New York University |
Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
|
US9700881B2
(en)
|
2013-10-09 |
2017-07-11 |
Emory University |
Heterocyclic coupling catalysts and methods related thereto
|
EP3068392B9
(en)
|
2013-11-12 |
2021-08-04 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
KR20150062652A
(ko)
|
2013-11-29 |
2015-06-08 |
삼성전자주식회사 |
초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
|
CN106061480B
(zh)
|
2013-12-30 |
2020-02-28 |
莱福斯希医药公司 |
治疗性抑制性化合物
|
EP3114109A4
(en)
|
2014-03-07 |
2017-10-18 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
JP2015172005A
(ja)
|
2014-03-11 |
2015-10-01 |
国立大学法人 東京大学 |
鉄触媒によるカップリング化合物の製造方法
|
AU2015229117A1
(en)
|
2014-03-13 |
2016-09-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
US9790219B2
(en)
|
2014-03-13 |
2017-10-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
PL3424534T3
(pl)
|
2014-04-15 |
2021-11-22 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
AU2015255752B2
(en)
|
2014-05-08 |
2020-07-23 |
Immunoforge Co., Ltd. |
Methods and compositions for treating Cystic Fibrosis
|
PT3142701T
(pt)
|
2014-05-12 |
2018-10-18 |
Verona Pharma Plc |
Novo tratamento
|
US9326926B2
(en)
|
2014-05-16 |
2016-05-03 |
Liqwd, Inc. |
Keratin treatment formulations and methods
|
US10045979B2
(en)
|
2014-05-19 |
2018-08-14 |
Merial Inc. |
Anthelmintic compounds
|
JP6692759B2
(ja)
|
2014-06-05 |
2020-05-13 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
新規キノリン誘導体及び神経変性疾患におけるそれらの使用
|
US10174014B2
(en)
|
2014-06-19 |
2019-01-08 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
CN107105749A
(zh)
|
2014-08-13 |
2017-08-29 |
阿克索生物医药公司 |
抗微生物化合物和组合物及其用途
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
JP2017538659A
(ja)
|
2014-09-10 |
2017-12-28 |
エピザイム インコーポレイテッド |
Smyd阻害剤
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
WO2016050209A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种异官能化聚乙二醇衍生物、制备方法及其生物相关物质
|
US11324827B2
(en)
|
2014-10-01 |
2022-05-10 |
Xiamen Sinopeg Biotech Co., Ltd. |
Multifunctionalized polyethylene glycol derivative and preparation method therefor
|
WO2016050208A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种多官能化聚乙二醇衍生物修饰的生物相关物质
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
HUE051972T2
(hu)
|
2014-10-06 |
2021-04-28 |
Vertex Pharma |
Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai
|
CA2963640A1
(en)
|
2014-10-06 |
2016-04-14 |
Flatley Discovery Lab, Llc |
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
WO2016057811A1
(en)
|
2014-10-08 |
2016-04-14 |
Nivalis Therapeutics, Inc. |
Methods for the treatment of cystic fibrosis
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
EP3212201B1
(en)
|
2014-10-28 |
2022-10-19 |
BCI Pharma |
Nucleoside kinase inhibitors
|
BR112017009194A2
(pt)
|
2014-10-31 |
2017-12-26 |
Abbvie Sarl |
tetra-hidropiranos substituídos e método de uso
|
MX366556B
(es)
|
2014-10-31 |
2019-07-12 |
Abbvie Sarl |
Cromanos sustituidos y metodo de uso.
|
RU2691136C2
(ru)
|
2014-11-18 |
2019-06-11 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
|
WO2016086015A1
(en)
|
2014-11-25 |
2016-06-02 |
University Of Rochester |
Myoglobin-based catalysts for carbene transfer reactions
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
WO2016105477A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
WO2016105484A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
ES2737227T3
(es)
|
2014-12-24 |
2020-01-10 |
Kither Biotech S R L |
Péptido inhibidor de gamma PI3K novedoso para el tratamiento de enfermedades del sistema respiratorio
|
EA201791500A1
(ru)
|
2014-12-31 |
2018-01-31 |
Оспекс Фармасьютикалз, Инк. |
Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
|
WO2016107603A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
CA2981495C
(en)
|
2015-03-31 |
2023-09-26 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated vx-661
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|